Signal transducer and activator of transcription 3 (Stat3) is responsible for many aspects of normal development and contributes to the development and progression of cancer through regulating epithelial cell identity and cancer stem cells. In breast cancer, Stat3 is associated with triple-negative breast cancers (TNBC) and its function has been related to the activation of p63, itself a marker of basal-like TNBC and a master regulator of stem cell activities. Stat3 activation is controlled by dual phosphorylation at tyrosine 705 (pTyr705) and serine 727 (pSer727), although it is unclear whether these have equivalent effects, and whether they are related or independent events. To address these issues, we investigated Stat3 phosphorylation at the two sites by immunohistochemistry in 173 patients with TNBC. Stat3 phosphorylation was assessed by automated quantitative measurements of digitized scanned images and classified into four categories based on histoscore. The results were analyzed for associations with multiple markers of tumor phenotype, proliferation, BRCA status, and clinicopathological characteristics. We show that the levels of pTyr705- and pSer727-Stat3 were independent in 34% of tumors. High pTyr705-Stat3 levels were associated with the luminal differentiation markers ERβ/AR and MUC1, whereas tumors with high levels of pSer727-Stat3 were more likely to be positive for the basal marker CK5/6, but were independent of p63 and were EGFR negative. Combined high pSer727- and low Tyr705-Stat3 phosphorylation associated with basal-like cancer. Although high Stat3 phosphorylation levels were associated with less aggressive tumor characteristics, they did not associate with improved survival, indicating that Stat3 phosphorylation is an unfavorable indicator for tumors with an otherwise good prognosis according to clinicopathological characteristics. These findings also show that pTyr705-Stat3 and pSer727-Stat3 associate with specific breast tumor phenotypes, implying that they exert distinct functional activities in breast cancer.

Department of Experimental Biology Faculty of Science Masaryk University Brno Czechia

Masaryk Memorial Cancer Institute Research Center for Applied Molecular Oncology Brno Czechia

Zobrazit více v PubMed

Galoczova M, Coates P, Vojtesek B. STAT3, Stem Cells, Cancer Stem Cells and P63. Cell Mol Biol Lett (2018) 23:12. 10.1186/s11658-018-0078-0 PubMed DOI PMC

Hughes K, Watson CJ. The Multifaceted Role of STAT3 in Mammary Gland Involution and Breast Cancer. Int J Mol Sci (2018) 19:E1695. 10.3390/ijms19061695 PubMed DOI PMC

Resemann HK, Watson CJ, Lloyd-Lewis B. The Stat3 Paradox: a Killer and an Oncogene. Mol Cel Endocrinol (2014) 382:603–11. 10.1016/j.mce.2013.06.029 PubMed DOI

Philp JA, Burdon TG, Watson CJ. Differential Activation of STATs 3 and 5 during Mammary Gland Development. FEBS Lett (1996) 396:77–80. 10.1016/0014-5793(96)01069-1 PubMed DOI

Banerjee K, Resat H. Constitutive Activation of STAT3 in Breast Cancer Cells: A Review. Int J Cancer (2016) 138:2570–8. 10.1002/ijc.29923 PubMed DOI PMC

Qin J-J, Yan L, Zhang J, Zhang W-D. STAT3 as a Potential Therapeutic Target in Triple Negative Breast Cancer: a Systematic Review. J Exp Clin Cancer Res (2019) 38:195. 10.1186/s13046-019-1206-z PubMed DOI PMC

Pokorná Z, Vysloužil J, Hrabal V, Vojtěšek B, Coates PJ. The Foggy World(s) of P63 Isoform Regulation in normal Cells and Cancer. J Pathol (2021) 254:454–73. 10.1002/path.5656 PubMed DOI

Fisher ML, Balinth S, Mills AA. p63-related Signaling at a Glance. J Cel Sci (2020) 133:jcs228015. 10.1242/jcs.228015 PubMed DOI PMC

Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, et al. Mammalian Target of Rapamycin Regulates Murine and Human Cell Differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest (2010) 120:103–14. 10.1172/JCI37964 PubMed DOI PMC

Chu W-K, Dai P-M, Li H-L, Chen J-K. Transcriptional Activity of the DeltaNp63 Promoter Is Regulated by STAT3. J Biol Chem (2008) 283:7328–37. 10.1074/jbc.M800183200 PubMed DOI

Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, et al. The Prognostic Significance of STAT3 in Invasive Breast Cancer: Analysis of Protein and mRNA Expressions in Large Cohorts. Breast Cancer Res Treat (2016) 156:9–20. 10.1007/s10549-016-3709-z PubMed DOI

Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue Microarray Analysis of Signal Transducers and Activators of Transcription 3 (Stat3) and Phospho-Stat3 (Tyr705) in Node-Negative Breast Cancer Shows Nuclear Localization Is Associated with a Better Prognosis. Clin Cancer Res (2003) 9:594–600. PubMed

Li Y, Wang Y, Shi Z, Liu J, Zheng S, Yang J, et al. Clinicopathological and Prognostic Role of STAT3/p-STAT3 in Breast Cancer Patients in China: A Meta-Analysis. Sci Rep (2019) 9:11243. 10.1038/s41598-019-47556-z PubMed DOI PMC

Liu Y, Huang J, Li W, Chen Y, Liu X, Wang J, et al. Meta-analysis of STAT3 and Phospho-STAT3 Expression and Survival of Patients with Breast Cancer. Oncotarget (2018) 9:13060–7. 10.18632/oncotarget.23962 PubMed DOI PMC

Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, et al. Prognostic Role of STAT3 in Solid Tumors: a Systematic Review and Meta-Analysis. Oncotarget (2016) 7:19863–83. 10.18632/oncotarget.7887 PubMed DOI PMC

Liu Z, Ge X, Gu Y, Huang Y, Liu H, Yu M, et al. Small Molecule STAT3 Inhibitor, 6Br-6a Suppresses Breast Cancer Growth In Vitro and In Vivo . Biomed Pharmacother (2020) 121:109502. 10.1016/j.biopha.2019.109502 PubMed DOI

Levy DE, Darnell JE. Stats: Transcriptional Control and Biological Impact. Nat Rev Mol Cel Biol (2002) 3:651–62. 10.1038/nrm909 PubMed DOI

Wen Z, Zhong Z, Darnell JE. Maximal Activation of Transcription by Stat1 and Stat3 Requires Both Tyrosine and Serine Phosphorylation. Cell (1995) 82:241–50. 10.1016/0092-8674(95)90311-9 PubMed DOI

Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of Serine Phosphorylation for Formation of STAT-Promoter Complexes. Science (1995) 267:1990–4. 10.1126/science.7701321 PubMed DOI

Shi X, Zhang H, Paddon H, Lee G, Cao X, Pelech S, et al. Phosphorylation of STAT3 Serine-727 by Cyclin-dependent Kinase 1 Is Critical for Nocodazole-Induced Mitotic Arrest. Biochemistry (2006) 45:5857–67. 10.1021/bi052490j PubMed DOI

Frank DA, Mahajan S, Ritz J. B Lymphocytes from Patients with Chronic Lymphocytic Leukemia Contain Signal Transducer and Activator of Transcription (STAT) 1 and STAT3 Constitutively Phosphorylated on Serine Residues. J Clin Invest (1997) 100:3140–8. 10.1172/JCI119869 PubMed DOI PMC

Liu H, Ma Y, Cole SM, Zander C, Chen K-H, Karras J, et al. Serine Phosphorylation of STAT3 Is Essential for Mcl-1 Expression and Macrophage Survival. Blood (2003) 102:344–52. 10.1182/blood-2002-11-3396 PubMed DOI

Qin HR, Kim H-J, Kim J-Y, Hurt EM, Klarmann GJ, Kawasaki BT, et al. Activation of Signal Transducer and Activator of Transcription 3 through a Phosphomimetic Serine 727 Promotes Prostate Tumorigenesis Independent of Tyrosine 705 Phosphorylation. Cancer Res (2008) 68:7736–41. 10.1158/0008-5472.CAN-08-1125 PubMed DOI PMC

Avalle L, Camporeale A, Morciano G, Caroccia N, Ghetti E, Orecchia V, et al. STAT3 Localizes to the ER, Acting as a Gatekeeper for ER-Mitochondrion Ca2+ Fluxes and Apoptotic Responses. Cell Death Differ (2019) 26:932–42. 10.1038/s41418-018-0171-y PubMed DOI PMC

D’Amico S, Shi J, Martin BL, Crawford HC, Petrenko O, Reich NC, et al. STAT3 Is a Master Regulator of Epithelial Identity and KRAS-Driven Tumorigenesis. Genes Dev (2018) 32:1175–87. 10.1101/gad.311852.118 PubMed DOI PMC

Huang G, Yan H, Ye S, Tong C, Ying Q-L. STAT3 Phosphorylation at Tyrosine 705 and Serine 727 Differentially Regulates Mouse ESC Fates. Stem Cells (2014) 32:1149–60. 10.1002/stem.1609 PubMed DOI PMC

Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, et al. p63 Isoforms in Triple-Negative Breast Cancer: ΔNp63 Associates with the Basal Phenotype whereas TAp63 Associates with Androgen Receptor, Lack of BRCA Mutation, PTEN and Improved Survival. Virchows Arch (2018) 472:351–9. 10.1007/s00428-018-2324-2 PubMed DOI

Siersbæk R, Scabia V, Nagarajan S, Chernukhin I, Papachristou EK, Broome R, et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. Cancer Cell (2020) 38:412–23. 10.1016/j.ccell.2020.06.007 PubMed DOI PMC

Koyama Y, Sumie S, Nakano Y, Nagao T, Tokumaru S, Michinaga S, et al. Endothelin-1 Stimulates Expression of Cyclin D1 and S-phase Kinase-Associated Protein 2 by Activating the Transcription Factor STAT3 in Cultured Rat Astrocytes. J Biol Chem (2019) 294:3920–33. 10.1074/jbc.RA118.005614 PubMed DOI PMC

Yeh Y-T, Ou-Yang F, Chen I-F, Yang S-F, Wang Y-Y, Chuang H-Y, et al. STAT3 Ser727 Phosphorylation and its Association with Negative Estrogen Receptor Status in Breast Infiltrating Ductal Carcinoma. Int J Cancer (2006) 118:2943–7. 10.1002/ijc.21771 PubMed DOI

Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open Source Software for Digital Pathology Image Analysis. Sci Rep (2017) 7:16878. 10.1038/s41598-017-17204-5 PubMed DOI PMC

Lucijanić M. Survival Analysis in Clinical Practice: Analyze Your Own Data Using an Excel Workbook. Croat Med J (2016) 57:77–9. 10.3325/cmj.2016.57.77 PubMed DOI PMC

Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, et al. Signal Transducer and Activator of Transcription-3 and Breast Cancer Prognosis. Am J Cancer Res (2011) 1:347–55. PubMed PMC

Segatto I, Baldassarre G, Belletti B. STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context. Int J Mol Sci (2018) 19:E2818. 10.3390/ijms19092818 PubMed DOI PMC

Kim S-Y, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, et al. Role of the IL-6-JAK1-STAT3-Oct-4 Pathway in the Conversion of Non-stem Cancer Cells into Cancer Stem-like Cells. Cell Signal (2013) 25:961–9. 10.1016/j.cellsig.2013.01.007 PubMed DOI PMC

Lehmann BD, Pietenpol JA. Identification and Use of Biomarkers in Treatment Strategies for Triple-Negative Breast Cancer Subtypes. J Pathol (2014) 232:142–50. 10.1002/path.4280 PubMed DOI PMC

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clin Cancer Res (2015) 21:1688–98. 10.1158/1078-0432.CCR-14-0432 PubMed DOI PMC

Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, et al. MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop. Sci Signal (2011) 4:ra9. 10.1126/scisignal.2001426 PubMed DOI PMC

Larsen MJ, Kruse TA, Tan Q, Lænkholm A-V, Bak M, Lykkesfeldt AE, et al. Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling. PLoS ONE (2013) 8:e64268. 10.1371/journal.pone.0064268 PubMed DOI PMC

McIntosh MT, Koganti S, Boatwright JL, Li X, Spadaro SV, Brantly AC, et al. STAT3 Imparts BRCAness by Impairing Homologous Recombination Repair in Epstein-Barr Virus-Transformed B Lymphocytes. PLoS Pathog (2020) 16:e1008849. 10.1371/journal.ppat.1008849 PubMed DOI PMC

Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like Breast Cancer Defined by Five Biomarkers Has superior Prognostic Value Than Triple-Negative Phenotype. Clin Cancer Res (2008) 14:1368–76. 10.1158/1078-0432.CCR-07-1658 PubMed DOI

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. J Clin Invest (2011) 121:2750–67. 10.1172/JCI45014 PubMed DOI PMC

Lüönd F, Tiede S, Christofori G. Breast Cancer as an Example of Tumour Heterogeneity and Tumour Cell Plasticity during Malignant Progression. Br J Cancer (2021) 125:164–75. 10.1038/s41416-021-01328-7 PubMed DOI PMC

Pasha N, Turner NC. Understanding and Overcoming Tumor Heterogeneity in Metastatic Breast Cancer Treatment. Nat Cancer (2021) 2:680–92. 10.1038/s43018-021-00229-1 PubMed DOI

Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan J-L. Heterogeneity within Molecular Subtypes of Breast Cancer. Am J Physiol Cel Physiol (2021) 321:C343–C354. 10.1152/ajpcell.00109.2021 PubMed DOI PMC

Lee ATJ, Chew W, Wilding CP, Guljar N, Smith MJ, Strauss DC, et al. The Adequacy of Tissue Microarrays in the Assessment of Inter- and Intra-tumoural Heterogeneity of Infiltrating Lymphocyte burden in Leiomyosarcoma. Sci Rep (2019) 9:14602. 10.1038/s41598-019-50888-5 PubMed DOI PMC

Siegmund K, Shibata D. At Least Two Well-Spaced Samples Are Needed to Genotype a Solid Tumor. BMC Cancer (2016) 16:250. 10.1186/s12885-016-2202-8 PubMed DOI PMC

Huynh J, Chand A, Gough D, Ernst M. Therapeutically Exploiting STAT3 Activity in Cancer - Using Tissue Repair as a Road Map. Nat Rev Cancer (2019) 19:82–96. 10.1038/s41568-018-0090-8 PubMed DOI

Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, Thompson AM, et al. Lack of Correlation of Stem Cell Markers in Breast Cancer Stem Cells. Br J Cancer (2014) 110:2063–71. 10.1038/bjc.2014.105 PubMed DOI PMC

Zhang R, Tu J, Liu S. Novel Molecular Regulators of Breast Cancer Stem Cell Plasticity and Heterogeneity. Semin Cancer Biol (2022) 82:11–25. 10.1016/j.semcancer.2021.03.008 PubMed DOI

Zeng X, Liu C, Yao J, Wan H, Wan G, Li Y, et al. Breast Cancer Stem Cells, Heterogeneity, Targeting Therapies and Therapeutic Implications. Pharmacol Res (2021) 163:105320. 10.1016/j.phrs.2020.105320 PubMed DOI

Kim J, Villadsen R, Sørlie T, Fogh L, Grønlund SZ, Fridriksdottir AJ, et al. Tumor Initiating but Differentiated Luminal-like Breast Cancer Cells Are Highly Invasive in the Absence of Basal-like Activity. Proc Natl Acad Sci U S A (2012) 109:6124–9. 10.1073/pnas.1203203109 PubMed DOI PMC

Liu Y, Nekulova M, Nenutil R, Horakova I, Appleyard MV, Murray K, et al. ∆Np63/p40 Correlates with the Location and Phenotype of Basal/mesenchymal Cancer Stem-like Cells in Human ER+ and HER2+ Breast Cancers. J Pathol Clin Res (2020) 6:83–93. 10.1002/cjp2.149 PubMed DOI PMC

Galoczova M, Nenutil R, Pokorna Z, Vojtesek B, Coates PJ. TAp63 and ΔNp63 (P40) in Prostate Adenocarcinomas: ΔNp63 Associates with a Basal-like Cancer Stem Cell Population but Not with Metastasis. Virchows Arch (2021) 478:627–36. 10.1007/s00428-020-02944-z PubMed DOI

Holcakova J, Nekulova M, Orzol P, Nenutil R, Podhorec J, Svoboda M, et al. ΔNp63 Activates EGFR Signaling to Induce Loss of Adhesion in Triple-Negative Basal-like Breast Cancer Cells. Breast Cancer Res Treat (2017) 163:475–84. 10.1007/s10549-017-4216-6 PubMed DOI

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 163:506–19. 10.1016/j.cell.2015.09.033 PubMed DOI PMC

Gujam FJA, McMillan DC, Edwards J. The Relationship between Total and Phosphorylated STAT1 and STAT3 Tumour Cell Expression, Components of Tumour Microenvironment and Survival in Patients with Invasive Ductal Breast Cancer. Oncotarget (2016) 7:77607–21. 10.18632/oncotarget.12730 PubMed DOI PMC

Nilsson L, Sandén E, Khazaei S, Tryggvadottir H, Nodin B, Jirström K, et al. Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis. Front Oncol (2020) 10:1278. 10.3389/fonc.2020.01278 PubMed DOI PMC

Hsieh F-C, Cheng G, Lin J. Evaluation of Potential Stat3-Regulated Genes in Human Breast Cancer. Biochem Biophys Res Commun (2005) 335:292–9. 10.1016/j.bbrc.2005.07.075 PubMed DOI

Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O, et al. The STAT3 Oncogene as a Predictive Marker of Drug Resistance. Trends Mol Med (2007) 13:4–11. 10.1016/j.molmed.2006.11.001 PubMed DOI

Ma J-H, Qin L, Li X. Role of STAT3 Signaling Pathway in Breast Cancer. Cell Commun Signal (2020) 18:33. 10.1186/s12964-020-0527-z PubMed DOI PMC